Developer docs
API playgroundTry for free, no card

Search company profiles

Remegen

Full company profile

uuid0000c38

Namestring
Remegen
Legal namestring
RemeGen Co., Ltd. (荣昌生物制药(烟台)股份有限公司)
Websiteurl
remegen.com
Company typeenum
Public
Founded yearint
2008
Descriptiontext

RemeGen Co., Ltd. (荣昌生物制药(烟台)股份有限公司) is a Chinese biopharmaceutical company founded in 2008 in Yantai, Shandong, that discovers, develops, manufactures, and commercializes innovative biologics for autoimmune diseases, oncology, and ophthalmology. Its two commercial products are Telitacicept (RC18, brand Tai'ai), the world's first approved BLyS/APRIL dual-target fusion protein with five approved indications in China including systemic lupus erythematosus, rheumatoid arthritis, generalized myasthenia gravis, Sjögren's disease, and IgA nephropathy; and Disitamab Vedotin (RC48, brand Aidixi), China's first independently developed antibody-drug conjugate (ADC) targeting HER2 with five approved indications spanning gastric cancer, urothelial carcinoma, and breast cancer. The technology foundation consists of four integrated platforms: an antibody/fusion protein platform with hybridoma and display-based screening and 70,000-liter GMP manufacturing capacity; an ADC platform based on proprietary Thiel-bridge site-specific conjugation chemistry; a HiBody bispecific antibody platform; and a PR-ADC payload-recovery platform. R&D operations span Yantai, Beijing, Shanghai, and South San Francisco.

RemeGen monetizes through three revenue streams: domestic commercial product sales reimbursed under China's National Reimbursement Drug List (NRDL), generating 2,271 million yuan in 2025 product sales; outbound licensing of ex-Greater China rights to top-tier global pharmaceutical partners (AbbVie for RC148, Vor Bio for Telitacicept, Pfizer/Seagen for Disitamab Vedotin, Santen for RC28-E), with cumulative potential deal value exceeding $12.6 billion; and future royalty streams from those licensed territories. The company serves patients in China through a direct sales infrastructure of approximately 1,400 medical representatives covering over 2,000 hospitals across autoimmune and oncology specialty departments, supported by medical affairs and KOL engagement programs at major academic conferences (ASCO, ESMO, EULAR, ASCO-GU). RemeGen is dual-listed on the Hong Kong Stock Exchange (09995.HK, since 2020) and the Shanghai STAR Market (688331.SH, since 2022), reported 2025 revenue of 3,251 million yuan (+89% YoY) with 710 million yuan in net profit, and treats patients via its core clinical value proposition of first-in-class or best-in-class targeted biologics in indications previously limited to corticosteroids, broad immunosuppressants, or chemotherapy.

Short descriptiontext

RemeGen is a Chinese biopharmaceutical company that develops and commercializes innovative biologics for autoimmune diseases, oncology, and ophthalmology, anchored by Telitacicept (world's first BLyS/APRIL dual-target fusion protein) and Disitamab Vedotin (China's first independently developed HER2 ADC), distributed through 2,000+ Chinese hospitals and out-licensed globally to partners including AbbVie, Pfizer, Vor Bio, and Santen.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersYantai, China
HQ citystring
Yantai
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antibody drug conjugates, biologic therapeutics, autoimmune disease treatments, oncology biologics, fusion protein drugs
Industry5 codes
PRIMARYHLAAAAAB
Recombinant Protein Therapeutics (enzymes, hormones, growth factors)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceuticals
No data
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Domestic Commercial Product Sales
TypeOne Time License
Description

RemeGen generates revenue from domestic sales of its approved innovative biologics in China, including Telitacicept (RC18) and Disitamab Vedotin (RC48). Sales are made through hospital procurement channels and reimbursed via the National Reimbursement Drug List (NRDL). In 2025, domestic product sales reached 22.71 billion yuan, up 34% year-over-year, with 2025 full-year revenue of 32.51 billion yuan (+89.36%). The company is profitable with 2025 net profit of 710 million yuan.

remegen.com
2Outbound Licensing (Milestone Payments and Royalties)
TypeLicensing Royalties
Description

RemeGen licenses its proprietary drug candidates to international pharmaceutical partners (AbbVie, Vor Bio, Pfizer/Seagen, Santen) for development and commercialization outside Greater China. The company receives upfront payments, development/regulatory milestones, and tiered royalties on net sales. Key deals include AbbVie for RC148 ($650M upfront, up to $4.95B milestones + royalties), Vor Bio for Telitacicept ($45M upfront + warrants + up to $4B milestones), Pfizer/Seagen for RC48 ($2.6B), and Santen for RC28-E (RMB 250M upfront + milestones).

prnewswire.com
3Cumulative Sales and Patient Reach
TypeSubscription Recurring
Description

Cumulative sales of approved products have exceeded 5 billion yuan (RMB), with over 100,000 patients benefiting from treatment. Telitacicept sales in 2025 reached 1.387 billion yuan, growing 41.94% year-over-year with 2.255 million vials sold. Disitamab Vedotin sold 301,900 vials in 2025 (+27.31% YoY).

remegen.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure
Pricing details1 tier
1Telitacicept and Disitamab Vedotin are reimbursed under China's NRDL following price negotiations.
ModelSubscriptionBilling cadenceAnnual
Notes

Drug prices are negotiated with China's Healthcare Security Administration for NRDL inclusion. The company discloses that price reductions from NRDL negotiations were controlled at approximately 10%, better than market expectations of ~15%. Insurance coverage enhances patient access and drives volume growth.

remegen.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 6 records shown
1Telitacicept (泰它西普/泰爱®)
Description

World's first innovative dual-target biological medication targeting BLyS and APRIL for autoimmune diseases including systemic lupus erythematosus, rheumatoid arthritis, myasthenia gravis, Sjögren's syndrome, and IgA nephropathy

remegen.com
+5 more records
Core offering1 text field

RemeGen is a clinical-stage-to-commercial biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative biologics for autoimmune diseases, oncology, and ophthalmology. Its two commercially marketed products are Telitacicept (Tai'ai®, RC18), a BLyS/APRIL dual-target fusion protein approved for systemic lupus erythematosus, rheumatoid arthritis, generalized myasthenia gravis, Sjögren's syndrome, and IgA nephropathy, and Disitamab Vedotin (Aidixi®, RC48), a HER2-targeted antibody-drug conjugate approved for gastric cancer, urothelial carcinoma, and breast cancer. Revenue is generated through direct hospital sales in China under NRDL reimbursement and through global out-licensing of pipeline assets to multinational pharmaceutical partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 9 values shown
  • Telitacicept 52-week SRI-4 response rate of 82.6% in systemic lupus erythematosus
+8 more records
Product and service4 records
1Telitacicept (Tai'ai® / 泰爱®, RC18)
CategoryAutoimmune Biologics — Fusion Protein
Description

World's first BLyS/APRIL dual-target TACI-Fc fusion protein that simultaneously binds and neutralizes B-lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL) cytokines, blocking B-cell abnormal differentiation and maturation through dual pathway inhibition. Approved in China for systemic lupus erythematosus, rheumatoid arthritis, generalized myasthenia gravis, Sjögren's syndrome, and IgA nephropathy. Used by hospital rheumatologists, nephrologists, and neurologists for patients with B-cell-mediated autoimmune diseases.

2Disitamab Vedotin (Aidixi® / 爱地希®, RC48)
CategoryOncology Biologics — Antibody-Drug Conjugate
Description

China's first independently developed novel antibody-drug conjugate (ADC) targeting HER2, using a novel HER2-targeting antibody with higher affinity and improved internalization combined with an enzymatically cleavable MC-Val-Cit-PAB linker and MMAE payload to enable bystander killing of neighboring tumor cells. Approved in China for HER2-expressing gastric cancer, urothelial carcinoma, and breast cancer, and in development globally (via Pfizer/Seagen license) for HER2-expressing solid tumors.

3RC28
CategoryOphthalmology Biologics — Fusion Protein
Description

VEGF/FGF dual-target fusion protein simultaneously targeting angiogenesis and fibrosis pathways for treatment of ocular neovascular diseases including diabetic macular edema (DME), wet age-related macular degeneration (wAMD), and diabetic retinopathy (DR). Commercialization rights in Greater China and select Asian countries licensed to Santen Pharmaceutical.

4RC148
CategoryOncology Biologics — Bispecific Antibody
Description

PD-1/VEGF bispecific antibody simultaneously targeting PD-1 immune checkpoint and VEGF angiogenesis pathways to activate anti-tumor immune responses and inhibit tumor-driven angiogenesis. In clinical development for solid tumors including non-small cell lung cancer (NSCLC) and colorectal cancer. Global (ex-Greater China) rights licensed to AbbVie.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-01-12
Description

In January 2026, RemeGen granted AbbVie exclusive rights to develop, manufacture, and commercialize RC148 (PD-1/VEGF bispecific antibody) outside Greater China. RemeGen received $650 million upfront and is eligible for up to $4.95 billion in development, regulatory, and commercial milestone payments, plus tiered double-digit royalties on net sales. This represents one of the largest China-outbound licensing deals for a bispecific antibody.

2Santen
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-08-18
Description

In August 2025, RemeGen entered an exclusive licensing agreement with Santen Pharmaceutical (China) for RC28-E (VEGF/FGF dual-target fusion protein) in Greater China and select Asian countries (South Korea, Thailand, Vietnam, Singapore, Philippines, Indonesia, Malaysia). RemeGen received RMB 250 million upfront and is eligible for up to RMB 1.045 billion in development/regulatory milestones plus tiered royalties. RemeGen retains global rights outside the licensed territories.

remegen.com
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-06-25
Description

In June 2025, RemeGen out-licensed Telitacicept (RC18) to Vor Bio for development and commercialization outside Greater China. The deal included $45 million upfront, warrants giving a RemeGen subsidiary a 23% stake in Vor, a $175 million private placement, and potential milestones of up to $4 billion plus royalties. Vor Bio is advancing global Phase 3 trials in generalized myasthenia gravis and Sjogren's disease.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

RemeGen collaborated with Junshi Biosciences to conduct the RC48-C016 Phase III trial combining disitamab vedotin with toripalimab (Junshi's PD-1 inhibitor) for first-line treatment of HER2-expressing urothelial carcinoma. The combination therapy received NMPA approval in April 2026 and was published in NEJM. This represents a co-development and co-commercialization arrangement in China.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2021-08-01
Description

In August 2021, Seagen (subsequently acquired by Pfizer) licensed exclusive rights to develop and commercialize disitamab vedotin (RC48) outside the Asia-Pacific region for up to $2.6 billion in upfront and milestone payments plus tiered royalties. This deal set a record for the largest single-product overseas licensing by a Chinese pharma company at the time.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Chinese dual-listed (NASDAQ: ONC, HKEX: 6160) oncology biotech developing innovative biologics and small molecules including the PD-1 inhibitor tislelizumab. Comparable as a China-originated, dual-listed biotech with global out-licensing and direct commercialization ambitions across oncology and immunology.

TypeDirect peer
Description

Chinese innovative biologics company (HKEX: 1801) with commercial PD-1 (sintilimab) and a robust ADC and bispecific pipeline. Directly comparable to RemeGen as a China-headquartered developer of innovative biologics with NRDL-driven commercialization and selective out-licensing.

TypeDirect peer
Description

Chinese biotech (HKEX: 9926) specializing in bispecific antibodies, including ivonescimab (PD-1/VEGF). Directly comparable to RemeGen's RC148 program in the PD-1/VEGF bispecific category, with both companies focused on next-generation immuno-oncology biologics.

TypeDirect peer
Description

Chinese biotech (HKEX: 1877, SHA: 688180) that developed toripalimab — RemeGen's combination partner for disitamab vedotin. Comparable as a China-headquartered PD-1 developer with NRDL commercialization and selective global partnerships.

5Hengrui Medicine
TypeBroad incumbent
Description

China's largest innovative pharmaceutical company (SHA: 600276) with broad ADC, biologics, and small molecule portfolios. Comparable as a Chinese innovative pharma leader with NRDL-driven commercialization, though operating across many more therapeutic areas than RemeGen.

6Hansoh Pharmaceutical
TypeBroad incumbent
Description

Chinese innovative pharma company (HKEX: 3692) with biologics and small molecule portfolios across oncology and CNS. Comparable as a NRDL-active Chinese innovative pharma, though with a broader therapeutic footprint than RemeGen.

TypeOthers
Description

Global biologics CDMO (HKEX: 2269) providing development and manufacturing services for antibody and biologic drug developers. Comparable as a Chinese-headquartered biologics infrastructure provider relevant to RemeGen's manufacturing and platform strategy, though operating as a service provider rather than a product developer.

TypeBroad incumbent
Description

Global biopharmaceutical leader (NYSE: ABBV) with blockbuster autoimmune assets (Skyrizi, Rinvoq) and immuno-oncology portfolio. Comparable as a RemeGen licensing partner for RC148 and as a benchmark for autoimmune commercial scale.

TypeBroad incumbent
Description

Global biopharmaceutical company (NYSE: PFE) that acquired Seagen, RemeGen's partner for disitamab vedotin ex-Asia-Pacific. Comparable as a global oncology powerhouse with ADC franchise (Padcev) and as a RemeGen commercialization partner.

TypeBroad incumbent
Description

Global biopharmaceutical company (NASDAQ: AZN) with a major ADC franchise (Enhertu via Daiichi partnership) and significant immuno-oncology portfolio. Comparable as a global ADC and biologics leader whose franchise overlaps with RemeGen's Disitamab Vedotin positioning.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors18 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Remegen

Biopharmaceuticalsremegen.com

RemeGen is a Chinese biopharmaceutical company that develops and commercializes innovative biologics for autoimmune diseases, oncology, and ophthalmology, anchored by Telitacicept (world's first BLyS/APRIL dual-target fusion protein) and Disitamab Vedotin (China's first independently developed HER2 ADC), distributed through 2,000+ Chinese hospitals and out-licensed globally to partners including AbbVie, Pfizer, Vor Bio, and Santen.

What Remegen does

RemeGen Co., Ltd. (荣昌生物制药(烟台)股份有限公司) is a Chinese biopharmaceutical company founded in 2008 in Yantai, Shandong, that discovers, develops, manufactures, and commercializes innovative biologics for autoimmune diseases, oncology, and ophthalmology. Its two commercial products are Telitacicept (RC18, brand Tai'ai), the world's first approved BLyS/APRIL dual-target fusion protein with five approved indications in China including systemic lupus erythematosus, rheumatoid arthritis, generalized myasthenia gravis, Sjögren's disease, and IgA nephropathy; and Disitamab Vedotin (RC48, brand Aidixi), China's first independently developed antibody-drug conjugate (ADC) targeting HER2 with five approved indications spanning gastric cancer, urothelial carcinoma, and breast cancer. The technology foundation consists of four integrated platforms: an antibody/fusion protein platform with hybridoma and display-based screening and 70,000-liter GMP manufacturing capacity; an ADC platform based on proprietary Thiel-bridge site-specific conjugation chemistry; a HiBody bispecific antibody platform; and a PR-ADC payload-recovery platform. R&D operations span Yantai, Beijing, Shanghai, and South San Francisco.

RemeGen monetizes through three revenue streams: domestic commercial product sales reimbursed under China's National Reimbursement Drug List (NRDL), generating 2,271 million yuan in 2025 product sales; outbound licensing of ex-Greater China rights to top-tier global pharmaceutical partners (AbbVie for RC148, Vor Bio for Telitacicept, Pfizer/Seagen for Disitamab Vedotin, Santen for RC28-E), with cumulative potential deal value exceeding $12.6 billion; and future royalty streams from those licensed territories. The company serves patients in China through a direct sales infrastructure of approximately 1,400 medical representatives covering over 2,000 hospitals across autoimmune and oncology specialty departments, supported by medical affairs and KOL engagement programs at major academic conferences (ASCO, ESMO, EULAR, ASCO-GU). RemeGen is dual-listed on the Hong Kong Stock Exchange (09995.HK, since 2020) and the Shanghai STAR Market (688331.SH, since 2022), reported 2025 revenue of 3,251 million yuan (+89% YoY) with 710 million yuan in net profit, and treats patients via its core clinical value proposition of first-in-class or best-in-class targeted biologics in indications previously limited to corticosteroids, broad immunosuppressants, or chemotherapy.

Remegen firmographics

Firmographics
Name
Remegen
Legal name
RemeGen Co., Ltd. (荣昌生物制药(烟台)股份有限公司)
Website
https://remegen.com
Company type
Public
Founded year
2008
Operating status
Operating
Headcount range
1–10 employees
Short description
RemeGen is a Chinese biopharmaceutical company that develops and commercializes innovative biologics for autoimmune diseases, oncology, and ophthalmology, anchored by Telitacicept (world's first BLyS/APRIL dual-target fusion protein) and Disitamab Vedotin (China's first independently developed HER2 ADC), distributed through 2,000+ Chinese hospitals and out-licensed globally to partners including AbbVie, Pfizer, Vor Bio, and Santen.
Ownership category
akta.pro rank

Remegen industry classification

Industry
Product category
Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAB
Recombinant Protein Therapeutics (enzymes, hormones, growth factors)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Antibody drug conjugates
  • Biologic therapeutics
  • Autoimmune disease treatments
  • Oncology biologics
  • Fusion protein drugs

Where Remegen is headquartered

Location

Headquarters

HQ city
Yantai
HQ country
China
HQ region
Asia

Offices4 records

Markets served

Remegen business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. Domestic Commercial Product Sales: RemeGen generates revenue from domestic sales of its approved innovative biologics in China, including Telitacicept (RC18) and Disitamab Vedotin (RC48). Sales are made through hospital procurement channels and reimbursed via the National Reimbursement Drug List (NRDL). In 2025, domestic product sales reached 22.71 billion yuan, up 34% year-over-year, with 2025 full-year revenue of 32.51 billion yuan (+89.36%). The company is profitable with 2025 net profit of 710 million yuan.
  2. Outbound Licensing (Milestone Payments and Royalties): RemeGen licenses its proprietary drug candidates to international pharmaceutical partners (AbbVie, Vor Bio, Pfizer/Seagen, Santen) for development and commercialization outside Greater China. The company receives upfront payments, development/regulatory milestones, and tiered royalties on net sales. Key deals include AbbVie for RC148 ($650M upfront, up to $4.95B milestones + royalties), Vor Bio for Telitacicept ($45M upfront + warrants + up to $4B milestones), Pfizer/Seagen for RC48 ($2.6B), and Santen for RC28-E (RMB 250M upfront + milestones).
  3. Cumulative Sales and Patient Reach: Cumulative sales of approved products have exceeded 5 billion yuan (RMB), with over 100,000 patients benefiting from treatment. Telitacicept sales in 2025 reached 1.387 billion yuan, growing 41.94% year-over-year with 2.255 million vials sold. Disitamab Vedotin sold 301,900 vials in 2025 (+27.31% YoY).

Pricing tiers

ModelBillingPrice
SubscriptionAnnualTelitacicept and Disitamab Vedotin are reimbursed under China's NRDL following price negotiations.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Remegen product offering

Product offering

Core offering

RemeGen is a clinical-stage-to-commercial biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative biologics for autoimmune diseases, oncology, and ophthalmology. Its two commercially marketed products are Telitacicept (Tai'ai®, RC18), a BLyS/APRIL dual-target fusion protein approved for systemic lupus erythematosus, rheumatoid arthritis, generalized myasthenia gravis, Sjögren's syndrome, and IgA nephropathy, and Disitamab Vedotin (Aidixi®, RC48), a HER2-targeted antibody-drug conjugate approved for gastric cancer, urothelial carcinoma, and breast cancer. Revenue is generated through direct hospital sales in China under NRDL reimbursement and through global out-licensing of pipeline assets to multinational pharmaceutical partners.

Differentiator

Problem solved

Functional benefit

Brands

  • Telitacicept (泰它西普/泰爱®): World's first innovative dual-target biological medication targeting BLyS and APRIL for autoimmune diseases including systemic lupus erythematosus, rheumatoid arthritis, myasthenia gravis, Sjögren's syndrome, and IgA nephropathy
  • Disitamab Vedotin (维迪西妥单抗/爱地希®)
  • RC28
  • RC148
  • RC88
  • RC278

Products and services

  • Telitacicept (Tai'ai® / 泰爱®, RC18) World's first BLyS/APRIL dual-target TACI-Fc fusion protein that simultaneously binds and neutralizes B-lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL) cytokines, blocking B-cell abnormal differentiation and maturation through dual pathway inhibition. Approved in China for systemic lupus erythematosus, rheumatoid arthritis, generalized myasthenia gravis, Sjögren's syndrome, and IgA nephropathy. Used by hospital rheumatologists, nephrologists, and neurologists for patients with B-cell-mediated autoimmune diseases.
  • Disitamab Vedotin (Aidixi® / 爱地希®, RC48) China's first independently developed novel antibody-drug conjugate (ADC) targeting HER2, using a novel HER2-targeting antibody with higher affinity and improved internalization combined with an enzymatically cleavable MC-Val-Cit-PAB linker and MMAE payload to enable bystander killing of neighboring tumor cells. Approved in China for HER2-expressing gastric cancer, urothelial carcinoma, and breast cancer, and in development globally (via Pfizer/Seagen license) for HER2-expressing solid tumors.
  • RC28 VEGF/FGF dual-target fusion protein simultaneously targeting angiogenesis and fibrosis pathways for treatment of ocular neovascular diseases including diabetic macular edema (DME), wet age-related macular degeneration (wAMD), and diabetic retinopathy (DR). Commercialization rights in Greater China and select Asian countries licensed to Santen Pharmaceutical.
  • RC148 PD-1/VEGF bispecific antibody simultaneously targeting PD-1 immune checkpoint and VEGF angiogenesis pathways to activate anti-tumor immune responses and inhibit tumor-driven angiogenesis. In clinical development for solid tumors including non-small cell lung cancer (NSCLC) and colorectal cancer. Global (ex-Greater China) rights licensed to AbbVie.

Quantifiable outcome

  • Telitacicept 52-week SRI-4 response rate of 82.6% in systemic lupus erythematosus
  • +8 more outcomes

Companies that use Remegen

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles2 records

Remegen technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Remegen partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered flagship and core.

  • AbbVieflagshipStrategic or Co-development Partner · 12 January 2026In January 2026, RemeGen granted AbbVie exclusive rights to develop, manufacture, and commercialize RC148 (PD-1/VEGF bispecific antibody) outside Greater China. RemeGen received $650 million upfront and is eligible for up to $4.95 billion in development, regulatory, and commercial milestone payments, plus tiered double-digit royalties on net sales. This represents one of the largest China-outbound licensing deals for a bispecific antibody.
  • SantencoreStrategic or Co-development Partner · 18 August 2025In August 2025, RemeGen entered an exclusive licensing agreement with Santen Pharmaceutical (China) for RC28-E (VEGF/FGF dual-target fusion protein) in Greater China and select Asian countries (South Korea, Thailand, Vietnam, Singapore, Philippines, Indonesia, Malaysia). RemeGen received RMB 250 million upfront and is eligible for up to RMB 1.045 billion in development/regulatory milestones plus tiered royalties. RemeGen retains global rights outside the licensed territories.
  • Vor BioflagshipStrategic or Co-development Partner · 25 June 2025In June 2025, RemeGen out-licensed Telitacicept (RC18) to Vor Bio for development and commercialization outside Greater China. The deal included $45 million upfront, warrants giving a RemeGen subsidiary a 23% stake in Vor, a $175 million private placement, and potential milestones of up to $4 billion plus royalties. Vor Bio is advancing global Phase 3 trials in generalized myasthenia gravis and Sjogren's disease.
  • Junshi BiosciencescoreStrategic or Co-development Partner · 1 January 2024RemeGen collaborated with Junshi Biosciences to conduct the RC48-C016 Phase III trial combining disitamab vedotin with toripalimab (Junshi's PD-1 inhibitor) for first-line treatment of HER2-expressing urothelial carcinoma. The combination therapy received NMPA approval in April 2026 and was published in NEJM. This represents a co-development and co-commercialization arrangement in China.
  • Pfizer (formerly Seagen)flagshipStrategic or Co-development Partner · 1 August 2021In August 2021, Seagen (subsequently acquired by Pfizer) licensed exclusive rights to develop and commercialize disitamab vedotin (RC48) outside the Asia-Pacific region for up to $2.6 billion in upfront and milestone payments plus tiered royalties. This deal set a record for the largest single-product overseas licensing by a Chinese pharma company at the time.

Scale indicators12 records

Recent moves6 records

Expansion highlights6 records

Remegen competitors and assessment

Company assessment

Direct peers

  • BeiGene: Chinese dual-listed (NASDAQ: ONC, HKEX: 6160) oncology biotech developing innovative biologics and small molecules including the PD-1 inhibitor tislelizumab. Comparable as a China-originated, dual-listed biotech with global out-licensing and direct commercialization ambitions across oncology and immunology.
  • Innovent Biologics: Chinese innovative biologics company (HKEX: 1801) with commercial PD-1 (sintilimab) and a robust ADC and bispecific pipeline. Directly comparable to RemeGen as a China-headquartered developer of innovative biologics with NRDL-driven commercialization and selective out-licensing.
  • Akeso: Chinese biotech (HKEX: 9926) specializing in bispecific antibodies, including ivonescimab (PD-1/VEGF). Directly comparable to RemeGen's RC148 program in the PD-1/VEGF bispecific category, with both companies focused on next-generation immuno-oncology biologics.
  • Junshi Biosciences: Chinese biotech (HKEX: 1877, SHA: 688180) that developed toripalimab — RemeGen's combination partner for disitamab vedotin. Comparable as a China-headquartered PD-1 developer with NRDL commercialization and selective global partnerships.

Broad incumbents

  • Hengrui Medicine: China's largest innovative pharmaceutical company (SHA: 600276) with broad ADC, biologics, and small molecule portfolios. Comparable as a Chinese innovative pharma leader with NRDL-driven commercialization, though operating across many more therapeutic areas than RemeGen.
  • Hansoh Pharmaceutical: Chinese innovative pharma company (HKEX: 3692) with biologics and small molecule portfolios across oncology and CNS. Comparable as a NRDL-active Chinese innovative pharma, though with a broader therapeutic footprint than RemeGen.
  • AbbVie: Global biopharmaceutical leader (NYSE: ABBV) with blockbuster autoimmune assets (Skyrizi, Rinvoq) and immuno-oncology portfolio. Comparable as a RemeGen licensing partner for RC148 and as a benchmark for autoimmune commercial scale.
  • Pfizer: Global biopharmaceutical company (NYSE: PFE) that acquired Seagen, RemeGen's partner for disitamab vedotin ex-Asia-Pacific. Comparable as a global oncology powerhouse with ADC franchise (Padcev) and as a RemeGen commercialization partner.
  • AstraZeneca: Global biopharmaceutical company (NASDAQ: AZN) with a major ADC franchise (Enhertu via Daiichi partnership) and significant immuno-oncology portfolio. Comparable as a global ADC and biologics leader whose franchise overlaps with RemeGen's Disitamab Vedotin positioning.

Others

  • WuXi Biologics: Global biologics CDMO (HKEX: 2269) providing development and manufacturing services for antibody and biologic drug developers. Comparable as a Chinese-headquartered biologics infrastructure provider relevant to RemeGen's manufacturing and platform strategy, though operating as a service provider rather than a product developer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Remegen financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Remegen leadership team

Management profile

Number of profiles

Profiles14 records

Remegen funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Remegen M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Remegen

What does Remegen do?

RemeGen is a clinical-stage-to-commercial biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative biologics for autoimmune diseases, oncology, and ophthalmology. Its two commercially marketed products are Telitacicept (Tai'ai®, RC18), a BLyS/APRIL dual-target fusion protein approved for systemic lupus erythematosus, rheumatoid arthritis, generalized myasthenia gravis, Sjögren's syndrome, and IgA nephropathy, and Disitamab Vedotin (Aidixi®, RC48), a HER2-targeted antibody-drug conjugate approved for gastric cancer, urothelial carcinoma, and breast cancer. Revenue is generated through direct hospital sales in China under NRDL reimbursement and through global out-licensing of pipeline assets to multinational pharmaceutical partners.

Is Remegen a public or private company?

Remegen is a public company. It is classified as public and is currently operating.

When was Remegen founded?

Remegen was founded in 2008. It employs 1 to 10 people.

Where is Remegen based?

Remegen is headquartered in Yantai, China, in the Asia region.

How does Remegen make money?

Three revenue lines are on record. Domestic Commercial Product Sales are the primary driver. The others are outbound Licensing (Milestone Payments and Royalties) and cumulative Sales and Patient Reach.

Who are Remegen's main competitors?

Direct peers on record are BeiGene, Innovent Biologics, Akeso and Junshi Biosciences. Broad incumbents are Hengrui Medicine, Hansoh Pharmaceutical, AbbVie, Pfizer and AstraZeneca. WuXi Biologics is listed as an others.

Does Remegen have an API?

No public API is recorded for Remegen.

What industry is Remegen in?

Remegen's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAB, Recombinant Protein Therapeutics (enzymes, hormones, growth factors), with a secondary code of HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewVor Bio, RemeGen expand collaboration to add autoimmune disease therapyVor Bio amended its agreement with RemeGen to add dual BAFF/APRIL inhibitor RC298, paying up to $356M. The deal includes $56M upfront and up to $300M in milestones, with an exclusive license outside Greater China. RC298 targets an IND in China in H1 2027.医药魔方-致力于数据赋能医药创新,助力高效决策与数智化转型RemeGen In-Licenses Pan-RAS(ON) Inhibitor in RMB 4.92bn DealRemeGen licensed a pan-RAS(ON) inhibitor from Rongchang Pharmaceutical, paying RMB 50 million upfront and up to RMB 4.87 billion in milestones plus tiered royalties. The lead compound RCZY-690 has cleared clinical trial initiation and dosed its first patient in September.The future of tradingRemeGen Publishes Presentation on Final Two-Year Results of Telitacicept Phase 3 IgA Nephropathy TrialRemeGen published final two-year results of the Phase 3 TELIGAN trial for telitacicept in IgA nephropathy. The drug's annualized eGFR slope was -0.6 mL/min/1.73 m², favoring telitacicept by 5.1 mL/min/1.73 m² annually, with urine protein-to-creatinine ratio reaching 0.40 times baseline versus 1.01 for placebo. Serious adverse events occurred in 8.2% of telitacicept patients versus 18.2% on placebo.Pharmaceutical TechnologyWhy CMC readiness is becoming central to biopharma licensing deals - Pharmaceutical TechnologyCMC readiness is becoming central to biopharma licensing deals, with CMC due diligence and CDMO expertise enhancing asset value. In 2025, US biopharma in-licensed an innovative drug from China in nearly 50% of agreements, and AbbVie signed a $5.6bn deal for RemeGen's RC148. Thermo Fisher recommends an audit-ready CMC package to strengthen confidence in scalability and commercialization.AInvestRemegen Co Ltd - agreed to purchase wealth management product of an amount of US$30.0 mln from OCBCRemegen Co Ltd has agreed to purchase a wealth management product from OCBC for US$30.0 million. This transaction represents a strategic investment or asset acquisition by Remegen in financial products offered by the banking group. The deal highlights ongoing business activities between the two entities in the financial sector.GlobalDataAPRIL therapy approval signals new phase of competition in IgA nephropathy market, says GlobalData – GlobalDataChina's National Medical Products Administration (NMPA) has approved RemeGen's Taiai (telitacicept) as the first dual BAFF/APRIL-targeting therapy for IgA nephropathy in adults, marking a significant advancement in a treatment landscape previously limited to corticosteroids and single-pathway drugs. Clinical trial data demonstrated a 58.9% reduction in urinary protein-to-creatinine ratio (UPCR) and significant decline in eGFR compared to ACEI/ARB treatment. The approval reflects broader efforts by Chinese biopharma companies to expand into nephrology and pursue international partnerships, with RemeGen having partnered with Vor Bio to develop and market Taiai outside China.Simply Wall StRemeGen (SEHK:9995) Stock Could Be 39% Below Fair Value After Telitacicept ApprovalsChina's National Medical Products Administration has approved new indications for RemeGen's autoimmune drug Telitacicept in Sjögren's disease and conditionally in IgA nephropathy, expanding the drug's addressable patient population. The company's stock trades at HK$68.5 against an analyst target of HK$114.72, suggesting a potential 39% discount to fair value, though the P/E ratio of 25.6x sits above the estimated fair P/E of 14.3x. Simply Wall St's DCF model places intrinsic value at HK$112.79, offering a mixed valuation picture as Telitacicept's commercial footprint grows.Stock TitanVor Bio: China NMPA approves telitacicept for Sjögren’sChina's National Medicinal Products Administration has approved telitacacept for the treatment of adult patients with Sjögren's disease, making it the first and only approved therapy for this indication in China. The approval was based on positive Phase 3 data from RemeGen showing statistically significant and clinically meaningful improvements in both ESSDAI and ESSPRI endpoints. This marks the fifth indication approval for telitacacept, with Vor Bio holding exclusive rights to develop and commercialize the drug outside Greater China.GlobeNewswireTelitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in ChinaChina's National Medicinal Products Administration (NMPA) has approved telitacicept for the treatment of adult patients with Sjögren's disease, making it the first and only approved therapy for this indication in China. The approval was supported by positive Phase 3 clinical trial data demonstrating statistically significant and clinically meaningful improvements in both ESSDAI and ESSPRI scores across 160 mg and 80 mg treatment groups. RemeGen independently developed telitacicept and holds responsibility for its development, regulatory approvals, and commercialization in China, while Vor Bio holds exclusive rights to develop and commercialize the therapy outside of Greater China.Stock TitanVor Bio: NMPA conditionally approves telitacicept for IgANChina's National Medicinal Products Administration (NMPA) has granted conditional approval for telitacicept to treat IgA nephropathy in adult patients, marking the first and only approved BAFF/APRIL-targeting therapy for this indication. The approval was supported by positive Phase 3 TELIGAN trial data showing a 59% reduction in urinary protein-to-creatinine ratio from baseline at Week 39, meeting the primary efficacy endpoint with a favorable safety profile. RemeGen developed telitacicept and holds responsibility for its development and commercialization in China, while Vor Bio retains exclusive rights to develop and commercialize the therapy outside Greater China, with global Phase 3 trials ongoing in generalized myasthenia gravis and Sjogren's disease.